Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

J Xu, L Shen, C Bai, W Wang, J Li, X Yu, Z Li… - The Lancet …, 2020 - thelancet.com
Background Surufatinib showed superior efficacy in extrapancreatic neuroendocrine
tumours (NETs) in the phase 3 SANET-ep study. In SANET-p, we aimed to assess the …
被引用次数：152 相关文章

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

J Xu, L Shen, C Bai, W Wang, J Li, X Yu… - The Lancet …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Surufatinib showed superior efficacy in extrapancreatic neuroendocrine
tumours (NETs) in the phase 3 SANET-ep study. In SANET-p, we aimed to assess the …

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.

J Xu, L Shen, C Bai, W Wang, J Li, X Yu, Z Li… - The Lancet …, 2020 - europepmc.org
Background Surufatinib showed superior efficacy in extrapancreatic neuroendocrine
tumours (NETs) in the phase 3 SANET-ep study. In SANET-p, we aimed to assess the …

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

J Xu, L Shen, C Bai, W Wang, J Li, X Yu, Z Li, E Li… - The Lancet …, 2020 - Elsevier
Background Surufatinib showed superior efficacy in extrapancreatic neuroendocrine
tumours (NETs) in the phase 3 SANET-ep study. In SANET-p, we aimed to assess the …